Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.529): a prospective cohort study from Shenzhen, China.

[1]  Gheyath K Nasrallah,et al.  Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study , 2022, The Lancet Microbe.

[2]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[3]  S. Hoehl,et al.  Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes , 2022, Science Immunology.

[4]  L. Walker,et al.  Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection , 2022, Science Immunology.

[5]  Shu Wan,et al.  SARS-CoV-2 Omicron variant: recent progress and future perspectives , 2022, Signal Transduction and Targeted Therapy.

[6]  D. McManus,et al.  Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness , 2022, Nature Microbiology.

[7]  N. Hulo,et al.  Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 , 2022, Nature Medicine.

[8]  A. Mann,et al.  Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults , 2022, Nature Medicine.

[9]  G. Lozanski,et al.  Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection , 2022, Science Translational Medicine.

[10]  Yi Shi,et al.  Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection , 2022, Nature Microbiology.

[11]  A. Kohl,et al.  Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants , 2022, Frontiers in Medicine.

[12]  S. Gordon,et al.  SARS-CoV-2 Variants, Vaccines, and Host Immunity , 2022, Frontiers in Immunology.

[13]  J. Li,et al.  Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees , 2022, Journal of Infection.

[14]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[15]  R. Peeling,et al.  Diagnostics for COVID-19: moving from pandemic response to control , 2021, The Lancet.

[16]  S. Kissler,et al.  Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons , 2021, The New England journal of medicine.

[17]  Elisabeth Mahase.  Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports , 2021, BMJ.

[18]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[19]  Yong Lin,et al.  Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects , 2021, Cellular & Molecular Immunology.

[20]  Zheng Wang,et al.  The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study , 2021, The Lancet Microbe.

[21]  C. Viboud,et al.  Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021 , 2021, Nature Human Behaviour.

[22]  L. Rénia,et al.  Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study , 2021, The Lancet Microbe.

[23]  D. Larremore,et al.  Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening , 2020, Science Advances.

[24]  M. Cevik,et al.  SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis , 2020, The Lancet Microbe.

[25]  D. Ho,et al.  Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies , 2020, PLoS biology.

[26]  M. Pascual,et al.  Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity , 2020, Proceedings of the National Academy of Sciences.

[27]  Jessina C. McGregor,et al.  Understanding Viral Shedding of SARS-CoV-2: Review of Current Literature. , 2020, Infection control and hospital epidemiology.

[28]  D. Raoult,et al.  Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[30]  S. Bhatt,et al.  Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study , 2020, The Lancet Infectious Diseases.

[31]  T. Liang,et al.  Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.

[32]  Jun Liu,et al.  Factors associated with prolonged viral RNA shedding in patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[34]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[35]  OUP accepted manuscript , 2022, Journal of Travel Medicine.